TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors.
TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138.
The absence of dose-limiting toxicities is a critical milestone for an RNA therapeutic, as safety remains a primary hurdle in early-stage oncology trials. Demonstrating dose-dependent plasma exposure further validates the compound's pharmacokinetic profile, suggesting that the drug behaves predictably in the body—a key factor for determining optimal dosing in later trials. The disease stabilization observed in some patients, while preliminary, offers an early signal of antitumor activity that warrants further investigation.
These results matter because they de-risk the next phase of development. For a clinical-stage company like TransCode, positive safety data can support regulatory discussions, attract partnership interest, and bolster investor confidence. The findings also reinforce the potential of targeting microRNA-10b, a well-documented biomarker of metastasis, as a viable strategy for treating advanced cancers.
TransCode's lead candidate, TTX-MC138, focuses on metastatic tumors that overexpress microRNA-10b. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and social media distribution to millions of followers, among other corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by InvestorWire, visit https://www.InvestorWire.com/Disclaimer.
